(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.27%.
Rani Therapeutics Holdings's earnings in 2026 is -$30,141,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$26,303,897, with the lowest RANI earnings forecast at -$27,321,483, and the highest RANI earnings forecast at -$24,882,064. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$29,858,477, with the lowest RANI earnings forecast at -$31,419,705, and the highest RANI earnings forecast at -$29,273,017.
In 2028, RANI is forecast to generate -$28,799,073 in earnings, with the lowest earnings forecast at -$31,419,705 and the highest earnings forecast at -$23,418,414.